New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
11:05 EDTRGP, IRWD, DMND, CMLP, WYN, JE, JNS, TPH, BKD, ALIMHigh option volume stocks
High option volume stocks: ALIM BKD TPH JNS JE WYN CMLP DMND IRWD RGP
News For ALIM;BKD;TPH;JNS;JE;WYN;CMLP;DMND;IRWD;RGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:08 EDTIRWDIronwood presents IW-9179 Phase IIa clinical study data
Subscribe for More Information
October 17, 2014
15:53 EDTALIMJames E. Flynn reports 5.58% passive stake in Alimera Sciences
Subscribe for More Information
October 16, 2014
15:10 EDTIRWDAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:02 EDTIRWDIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
07:23 EDTALIMIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
11:03 EDTWYNNew York AG reaches agreements with Hilton, Wyndham over timeshares
Subscribe for More Information
10:49 EDTRGPHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
October 13, 2014
17:15 EDTCMLPCrestwood Midstream says Q3 average natural gas gathering volumes up 5%
Subscribe for More Information
08:04 EDTJNSJanus to acquire VelocityShares, includes upfront cash consideration of $30M
Subscribe for More Information
October 10, 2014
07:32 EDTWYNWyndham aims to add 120 Caribbean, Latin America hotels by 2022, WSJ says
Subscribe for More Information
October 9, 2014
15:16 EDTRGPRegency Energy, Oneok interested in Nuevo Midstream sale, Bloomberg reports
Subscribe for More Information
07:59 EDTCMLPCrestwood Equity Crestwood Midstream weakness overdone, says Wells Fargo
After Crestwood Equity Partners LP(CEQP) and Crestwood Midstream Partners LP(CMLP) underperformed their broader group over the past month, Wells Fargo thinks the underperformance was driven by Quicksilver Resource's (KWK) financial struggles, concerns regarding gas storage fundamentals as it impacts Tres Palacios, and a decline in crude prices driving reduced activity in the Bakken. The firm believes that these concerns are legitimate, but it does not view them as new and calls the weakness in the stocks overdone. It keeps a Market Perform rating on Crestwood Equity Partners and an Outperform rating on Crestwood Midstream Partners.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use